Dark

Search

AXLA
Axcella Health Inc
stock NASDAQ

At Close

3/24/2023 3:59:54 PM EDT

0.4441USD+0.932%(+0.0041)26,267

0.3521Bid 0.5388Ask 0.1867Spread IEX

Pre-market

3/22/2023 9:07:30 AM EDT

0.4201USD-4.523%(-0.0199)0

After-hours

1969-12-31

0.00USD0.000%(0.00)0

Overview Option Chain HistoricalNews

Jan 6, 2022

07:58AM EST Axcella Therapeutics Details Clinical And Operational Milestones For 2022 Benzinga

Jan 4, 2022

07:58AM EST Axcella Therapeutics To Present At HC Wainwright BioConnect Conference Jan 10, 2022 At 7 a.m. EST Benzinga

Dec 16, 2021

07:29AM EST Axcella Therapeutics Announces Initiation Of AXA1125 Long COVID Phase 2a Clinical Trial Benzinga

Nov 16, 2021

09:29AM EST Chardan Capital Maintains Buy on Axcella Health, Raises Price Target to $12 Benzinga

Nov 10, 2021

07:58AM EST Axcella Health Q3 EPS $(0.41) Down From $(0.34) YoY Benzinga

Nov 8, 2021

08:29AM EST The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More Benzinga

Oct 26, 2021

06:58AM EDT Axcella Therapeutics Launched Clinical Program to Develop Treatment for Patients with Long COVID Benzinga

Oct 13, 2021

10:12AM EDT Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize PR Newswire

Oct 12, 2021

10:59AM EDT Noble Capital Markets Initiates Coverage On Axcella Health with Outperform Rating, Announces Price Target of $6 Benzinga

08:13AM EDT The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology Benzinga

Oct 6, 2021

07:33AM EDT The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal Benzinga

Oct 5, 2021

07:58AM EDT Axcella Announces Upcoming Investor Conference Presentation Oct. 12 Benzinga

Sep 30, 2021

09:51AM EDT From BZ's Small Cap Healthcare Conference: Axcella Health President & CEO, Bill Hinshaw Begins Speaking Benzinga

07:43AM EDT The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug Benzinga

Sep 28, 2021

10:57AM EDT Axcella's Leading Drug Candidate for Overt Hepatic Encephalopathy Offers Hope in a Market Requiring Innovation Benzinga

Sep 22, 2021

10:05AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2021 Benzinga

08:10AM EDT 10 Biggest Price Target Changes For Wednesday Benzinga

06:19AM EDT Goldman Sachs Downgrades Axcella Health to Neutral, Lowers Price Target to $5 Benzinga

Sep 9, 2021

09:49AM EDT Axcella's First-of-Its-Kind NASH Treatment Shows Promising Early Results in Human Trials Benzinga

Aug 30, 2021

01:21PM EDT Breakthrough Multi-Targeted Drug Candidates Puts Axcella at Forefront of Liver Disease Treatment Market Benzinga

Aug 16, 2021

07:58AM EDT Axcella Highlights Publication In The American Journal Of Gastroenterology Of Results From AXA1125-003 In Subjects With Presumed NASH Benzinga

Jul 30, 2021

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 30, 2021 Benzinga

06:37AM EDT JP Morgan Downgrades Axcella Health to Underweight Benzinga

Jul 29, 2021

08:03AM EDT Axcella Health Q2 EPS $(0.42) Beats $(0.43) Estimate Benzinga

04:23AM EDT Earnings Scheduled For July 29, 2021 Benzinga

Jul 6, 2021

10:04AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2021 Benzinga

06:30AM EDT HC Wainwright & Co. Initiates Coverage On Axcella Health with Buy Rating, Announces Price Target of $14 Benzinga

Jun 30, 2021

07:46AM EDT Axcella Initiates Phase 2 Trial Of AXA1665, Oral Product Candidate For Reduction In Risk Of Recurrent OHE RTTNews

07:29AM EDT Axcella Announces Initiation Of EMMPOWER Phase 2 Clinical Trial Of AXA1665 Benzinga

Jun 3, 2021

07:56AM EDT Chardan Capital Maintains Buy on Axcella Health, Lowers Price Target to $10 Benzinga

May 27, 2021

08:24AM EDT The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs Benzinga

May 26, 2021

07:33AM EDT The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing Benzinga

May 25, 2021

06:01AM EDT Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological PR Newswire

May 24, 2021

07:30AM EDT Axcella Presents Positive Data From AXA1665-002 Clinical Study At Digestive Disease Week 2021 Annual Meeting RTTNews

07:29AM EDT Axcella Highlights AXA1665 Presentation At DDW 2021 Benzinga

07:28AM EDT Positive Clinical Data About Axcella's AXA1665 Candidate for Overt Hepatic Encephalopathy Highlighted in Oral Presentation at DDW 2021 Business Wire

May 19, 2021

09:46AM EDT Invaio Sciences Announces Agreement With Fundecitrus In Brazil To Combat Against Citrus Greening RTTNews

09:04AM EDT Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat PR Newswire

May 12, 2021

08:57AM EDT The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron Benzinga

May 11, 2021

08:01AM EDT Axcella Begins EMMPACT Phase 2b Clinical Trial Of AXA1125 RTTNews

07:55AM EDT Axcella Announces Initiation of EMMPACT? Phase 2b Clinical Trial of AXA1125 Business Wire

07:54AM EDT The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings Benzinga

07:39AM EDT Axcella Begins EMMPACTSM Phase 2b Clinical Trial Of AXA1125 RTTNews

07:39AM EDT Axcella Announces Initiation Of EMMPACTSM Phase 2b Clinical Trial Of AXA1125 Benzinga

May 10, 2021

09:14AM EDT Axcella Health Posts Study Titled 'Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis' To ClinicalTrials.Gov Benzinga

May 7, 2021

07:40AM EDT The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs Benzinga

May 6, 2021

07:57AM EDT Axcella Health Q1 EPS $(0.40) Beats $(0.42) Estimate Benzinga

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

07:28AM EDT Axcella Reports First Quarter Financial Results and Provides Business Update Business Wire

04:17AM EDT Earnings Scheduled For May 6, 2021 Benzinga

Apr 27, 2021

07:28AM EDT Axcella to Report First Quarter 2021 Financial Results on May 6, 2021 Business Wire

Apr 22, 2021

07:30AM EDT Axcella To Present At Oral Presentation at Digestive Disease Week 2021 May 23rd Benzinga

07:28AM EDT Axcella Announces Upcoming Oral Presentation at Digestive Disease Week (DDW) 2021 Business Wire

Apr 15, 2021

05:47PM EDT Exclusive: Axcella Health Aims To Become The Standard Of Care Benzinga

01:16PM EDT EXCLUSIVE: Axcella Health CEO, Bill Hinshaw Says Co Is A Platform Company With Multiple Opportunities, Says Co Is Rapidly Processing Multiple Drugs To Treat Liver Diseases Benzinga

01:14PM EDT EXCLUSIVE: Axcella Health CEO, Bill Hinshaw Says By 2027 NASH Will Be A 7 Billion Plus Market, Says It Is Because NASH Is Very Complex Chronological Disease, Co Is Expected To Be One Of The Leaders To Treat NASH Benzinga

01:10PM EDT EXCLUSIVE: Axcella Health CEO, Bill Hinshaw Says More Than 40 Million Americans Have NASH, Says This Is A Complex Disease Benzinga

01:09PM EDT EXCLUSIVE: Axcella Health CEO, Bill Hinshaw Says Co Earlier Announced The Phase II Clinical Trials For Drug To Treat NASH Benzinga

01:06PM EDT EXCLUSIVE: Axcella Health CEO, Bill Hinshaw Now Interviewing On Benzinga's 'Power Hour' Show Benzinga

10:56AM EDT EXCLUSIVE: Axcella Health CEO, Bill Hinshaw To Appear On Benzinga's 'Power Hour' Show At 1 p.m. EDT Benzinga

Apr 13, 2021

07:31AM EDT Axcella Says AXA1125's IND Clearance For NASH, Enabling The Company To Proceed Directly Into Phase 2b Clinical Trial RTTNews

07:29AM EDT Axcella Announces AXA1125's IND Clearance for the Treatment of NASH Benzinga

Apr 9, 2021

09:19AM EDT Axcella's Multi-Targeted Approach To Treat Complex Diseases Holds Transformational Potential Benzinga

Mar 30, 2021

09:30AM EDT Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion PR Newswire

Mar 26, 2021

04:39PM EDT Highlights From Day 2 Of Benzinga's Biotech Small Cap Conference Benzinga

Mar 25, 2021

02:11PM EDT From BZ Biotech Conference: Axcella Health CEO Bill Hinshaw Says Seeking IND Submission/Clearance, Phase 2b Trial Initiation For Q2 2021; Says Phase 2b Trial Would Halve 48-Week Dosing Period, 2 Active Arms Vs Placebo Benzinga

02:09PM EDT From BZ Biotech Conference: Axcella Health CEO Bill Hinshaw Says Reductions Noted In Key Biomarkers With AXA1125 Benzinga

02:08PM EDT From BZ Biotech Conference: Axcella Health CEO Bill Hinshaw Highlights Co's AXA1125 Benzinga

02:07PM EDT From BZ Biotech Conference: Axcella Health CEO Bill Hinshaw Says Co Is Using A 'Rich, Expedited' Recruitment Process For AXA1665 Phase 2 Trial Benzinga

02:07PM EDT From BZ Biotech Conference: Axcella Health CEO Bill Hinshaw Says Recently Cleared IND With FDA; Expects Phase 2 Trial To Begin In Q2 Benzinga

02:06PM EDT From BZ Biotech Conference: Axcella Health CEO Bill Hinshaw Highlights Data From AXA1665-002; Says Showed Improvement In Key Biomakers Benzinga

02:03PM EDT From BZ Biotech Conference: Axcella Health CEO Bill Hinshaw Highlights Co's AXA1665 Benzinga

02:01PM EDT From BZ Biotech Conference: Axcella Health CEO Bill Hinshaw Says Co Using Machine Learning, Systems Biology To 'Identify Novel, Multi-Targeted Compositions' Benzinga

02:00PM EDT From BZ Biotech Conference: Axcella Health CEO Bill Hinshaw Co Wants To Work On 'Complex Diseases' Benzinga

01:59PM EDT From BZ Biotech Conference: Axcella Health CEO Bill Hinshaw Highlights Co's Endogenous Metabolic Modulators (EMMs) Benzinga

01:57PM EDT From BZ Biotech Conference: Axcella CEO Bill Hinshaw Begins Presentation Benzinga

Mar 17, 2021

07:36AM EDT Axcella Q4 Net Loss $15.2 Mln Or $0.40/shr Vs. Loss $15.7 Mln Or $0.68/shr Prior Year RTTNews

07:28AM EDT Axcella Health Q4 EPS $(0.40) Misses $(0.36) Estimate Benzinga

07:28AM EDT Axcella Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Business Wire

04:01AM EDT Earnings Scheduled For March 17, 2021 Benzinga

Mar 10, 2021

08:00AM EST Axcella to Report Fourth Quarter and Full Year 2020 Financial Results on March 17, 2021 Business Wire

Mar 3, 2021

04:20PM EST Axcella Announces Alison D. Schecter, M.D., as President of R&D Business Wire

Feb 25, 2021

07:55AM EST Axcella Announces Upcoming Presentations at NASH-TAG 2021 Business Wire

07:01AM EST Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target PR Newswire

Feb 18, 2021

07:55AM EST Axcella to Present at Upcoming Investor Conferences Business Wire

Jan 11, 2021

08:33AM EST Axcella Reports IND Clearance For AXA1665 RTTNews

07:59AM EST Axcella Announces IND Clearance For AXA1665 Program Updates, 2021 Milestone Benzinga

07:58AM EST Axcella Announces IND Clearance for AXA1665, Program Updates and 2021 Milestones Business Wire

Jan 5, 2021

07:58AM EST Axcella Announces Upcoming Presentation at J.P. Morgan Healthcare Conference Business Wire

Nov 20, 2020

07:30AM EST Axcella Announces Upcoming Investor Conference Presentation Business Wire

Nov 13, 2020

07:35AM EST Axcella Says Able To Demonstrate Clinically Relevant Multifactorial Effects With AXA1125 RTTNews

07:30AM EST Axcella Presents Data for AXA1125 at The Liver Meeting(r) 2020 Business Wire

Nov 12, 2020

07:54AM EST Axcella Q3 Loss/Shr $0.34 Vs Loss $0.75 Last Year RTTNews

07:44AM EST The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal Benzinga

07:39AM EST Axcella Health Q3 EPS $(0.34) Beats $(0.41) Estimate Benzinga

07:30AM EST Axcella Reports Third Quarter 2020 Financial Results and Provides Business Update Business Wire

04:18AM EST Earnings Scheduled For November 12, 2020 Benzinga

Oct 29, 2020

08:00AM EDT Axcella to Report Third Quarter 2020 Financial Results and Hold Conference Call on November 12, 2020 Business Wire

Oct 27, 2020

05:08AM EDT Chardan Capital Initiates Coverage On Axcella Health with Buy Rating, Announces Price Target of $16 Benzinga

Oct 26, 2020

06:48AM EDT SVB Leerink Assumes Axcella Health at Outperform, Announces Price Target of $10 Benzinga

Oct 2, 2020

07:58AM EDT Axcella Announces Upcoming Presentations at AASLD's The Liver Meeting(r) 2020 Business Wire

Sep 30, 2020

07:29AM EDT Axcella Highlights iScience Publication On 'Therapeutic Potential of Endogenous Metabolic Modulators (EMMs)' Benzinga

07:28AM EDT New Publication Highlights Therapeutic Potential of Endogenous Metabolic Modulators (EMMs) Business Wire

Sep 29, 2020

07:58AM EDT Axcella Announces Upcoming Investor Conference Presentation Business Wire

Sep 25, 2020

06:43AM EDT B. Riley FBR Initiates Coverage On Axcella Health with Buy Rating, Announces Price Target of $14 Benzinga

Sep 24, 2020

03:35PM EDT Company Profile for Axcella Health Inc. Business Wire

Sep 8, 2020

08:00AM EDT Axcella to Present at Upcoming Investor Conferences Business Wire

Aug 27, 2020

08:09AM EDT Axcella Highlights Late-Breaker Data From AXA1125-003 Clinical Study Presented At The EASL Digital International Liver Congress Benzinga

08:00AM EDT Axcella's Late-Breaker Data from AXA1125-003 Clinical Study Presented at the EASL Digital International Liver Congress Business Wire

Aug 20, 2020

07:30AM EDT Axcella Announces Upcoming Later-Breaker Presentation at The Digital International Liver Congress 2020 Business Wire

Aug 17, 2020

07:40AM EDT Axcella : Results Suggest AXA1665's Potential To Mitigate The Multifactorial Defects Of Hyperammonemia RTTNews

07:36AM EDT Results of Axcella's AXA1665-001 Clinical Study Published in Medical Journal Clinical and Translational Gastroenterology Benzinga

07:30AM EDT Results of Axcella's AXA1665-001 Clinical Study Published in Clinical and Translational Gastroenterology Business Wire

Aug 6, 2020

07:11AM EDT SVB Leerink Maintains Outperform on Axcella Health, Lowers Price Target to $10 Benzinga

Aug 5, 2020

10:41AM EDT CORRECTING and REPLACING Axcella Reports Positive Top-Line Data from AXA1665-002 and Second Quarter Financial Results Business Wire

07:52AM EDT Axcella Q2 Net Loss $13.9 Mln Or $0.48/Shr Vs Net Loss Of $14.4 mln Or $0.95/Shr Last Year RTTNews

07:51AM EDT Axcella Reports Top-Line Data From AXA1665-002Showing 'dose dependent improvements in markers of cognitive function and amino acid metabolism' Benzinga

07:30AM EDT Axcella Reports Positive Top-Line Data from AXA1665-002 and Second Quarter Financial Results Business Wire

04:21AM EDT Earnings Scheduled For August 5, 2020 Benzinga

Aug 3, 2020

08:00AM EDT Axcella to Report Second Quarter 2020 Financial Results and Hold Conference Call on August 5, 2020 Business Wire

Jul 31, 2020

12:43PM EDT Piper Sandler Initiates Coverage On Axcella Health with Overweight Rating, Announces Price Target of $25 Benzinga

Share